Silverback Therapeutics raises $85M Series C — six months after $78.5M — to fund SBT6050 Phase 1 work; total VC $210M

Seattle biotech Silverback Therapeutics raised an $85 million Series C just six months after a $78.5 million round to advance its ImmunoTAC platform and lead candidate SBT6050 in a Phase 1 study; total VC funding is $210 million. The company named Valerie Odegard president and chief scientific officer, Naomi Hunder chief medical officer, and appointed Laura Shawver as CEO in April.